Breathe out!

Close metadata

Choice of therapy in a patient with severe uncontrolled asthma.

Authors:

Nenasheva N.M.

«Russian Medical Academy of Continuous Professional Education

SPIN RSCI: 3363-6170
Scopus AuthorID: 57201763856
ORCID: 0000-0002-3162-2510

Peredelskaya M.Yu.

Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation;
LLC «Paracelsus Medical Center»

SPIN RSCI: 3336-5507
Scopus AuthorID: 57210586164
ORCID: 0000-0003-2682-8108

List of references:

Global Initiative for Asthma. 2022 GINA Report. Global Strategy for Asthma Management and Prevention [дата обращения 17 марта 2023]. Available from: GINA Main Report 2022 Front Cover (ginasthma.org).
Dávila González I, Moreno Benítez F, Quirce S. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma. J Investig Allergol Clin Immunol. 2019 Apr;29(2):8 4-93. https://doi.org/10.18176/jiaci.0385
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012 May 4;18(5):71 6-725. https://doi.org/10.1038/nm.2678
Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev. 2011 Jul;242(1):3 1-50. https://doi.org/10.1111/j.160 0-065X.2011.01020.x
Yu S, Kim HY, Chang YJ, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. J Allergy Clin Immunol. 2014 Apr;133(4):94 3-950; quiz 51. https://doi.org/10.1016/j.jaci.2014.02.015
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015 Jan;16(1):4 5-56. https://doi.org/10.1038/ni.3049
Lloyd CM, Snelgrove RJ. Type 2 immunity: Expanding our view. Sci Immunol. 2018 Jul 6;3(25): eaat1604. https://doi.org/10.1126/sciimmunol.aat1604
Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O’Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szefler SJ, Sullivan SD, Thomas MD, Wenzel SE, Reddel HK. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008 Sep;32(3):54 5-554. https://doi.org/10.1183/09031936.00155307
Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы, РРО 2021. Бронхиальная астма (2021) (spulmo.ru) [дата обращения 17.02.2023].
GINA DIFFICULT-TO-TREAT & SEVERE ASTHMA in adolescent and adult patients. Diagnosis and Management. A GINA Pocket Guide For Health Professionals. GINA-2022-severe-asthma-slide-set-2.pptx (live.com) [дата обращения 17.02.2023].
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):34 3-73. https://doi.org/10.1183/09031936.00202013
Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, Casale TB, Chan-Yeung M, Chen R, Chowdhury B, Chung KF, Dahl R, Drazen JM, Fabbri LM, Holgate ST, Kauffmann F, Haahtela T, Khaltaev N, Kiley JP, Masjedi MR, Mohammad Y, O’Byrne P, Partridge MR, Rabe KF, Togias A, van Weel C, Wenzel S, Zhong N, Zuberbier T. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010 Nov;126(5):92 6-938. https://doi.org/10.1016/j.jaci.2010.07.019
Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D’Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010 Feb 15;181(4):31 5-323. https://doi.org/10.1164/rccm.20090 6-0896OC
Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008 Aug 1;178(3):21 8-224. https://doi.org/10.1164/rccm.20071 1-1754OC
Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, Slama R, Jarvis D, Anto JM, Kauffmann F, Sunyer J. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011 Aug;38(2):31 0-317. https://doi.org/10.1183/09031936.00120810
Canonica GW, Colombo GL, Bruno GM, Di Matteo S, Martinotti C, Blasi F, Bucca C, Crimi N, Paggiaro P, Pelaia G, Passalaqua G, Senna G, Heffler E; SANI Network. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2019 Jan 26;12(1):100007. https://doi.org/10.1016/j.waojou.2018.12.001
Delgado J, Dávila IJ, Domínguez-Ortega J; Severe Asthma Group (SEAIC). Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement. J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):3 6-43. https://doi.org/10.18176/jiaci.0638
Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002 Jul;57(7):64 3-648. https://doi.org/10.1136/thorax.57.7.643
Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J. 2009 Oct;3(4):19 8-206. https://doi.org/10.1111/j.175 2-699X.2009.00162.x
Hudey SN, Ledford DK, Cardet JC. Mechanisms of non-type 2 asthma. Curr Opin Immunol. 2020 Oct;66:12 3-128. https://doi.org/10.1016/j.coi.2020.10.002
Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):54 6-555. https://doi.org/10.1111/cea.13790
Dunican EM, Fahy JV. Asthma and corticosteroids: time for a more precise approach to treatment. Eur Respir J. 2017 Jun 29;49(6):1701167. https://doi.org/10.1183/13993003.0116 7-2017
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall’acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125(6):134 4-1353.e2. https://doi.org/10.1016/j.jaci.2010.04.004
Cushen B, Menzies-Gow A. Benralizumab: an updated treatment of eosinophilic asthma. Expert Rev Respir Med. 2020 May;14(5):43 5-444. https://doi.org/10.1080/17476348.2020.1739526
Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, Terracciano R, Pelaia G. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. Biomed Res Int. 2018 May 10;2018:4839230. https://doi.org/10.1155/2018/4839230
Инструкция по применению бенрализумаба. Государственный реестр лекарственных средств (rosminzdrav.ru).
Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir. Med. 2016;111:2 1-29. https://doi.org/10.1016/j.rmed.2016.01.003
Zhu M, Yang J, Chen Y. Efficacy and safety of treatment with benralizumab for eosinophilic asthma. Int Immunopharmacol. 2022 Oct;111:109131. https://doi.org/10.1016/j.intimp.2022.109131
Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010 Jun;125(6):123 7-1244.e2. https://doi.org/10.1016/j.jaci.2010.04.005
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. J Allergy Clin Immunol. 2013 Nov;132(5):108 6-1096.e5. https://doi.org/10.1016/j.jaci.2013.05.020
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):212 8-2141. https://doi.org/10.1016/S0140-6736(16)31322-8
Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023 Jan;72(1):1 1-23. https://doi.org/10.1016/j.alit.2022.11.008
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):211 5-2127. https://doi.org/10.1016/S014 0-6736(16)3132 4-1
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 Jun 22;376(25):244 8-2458. https://doi.org/10.1056/NEJMoa1703501
Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, Gil EG. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021 Dec;9(12):438 1-4392.e4. https://doi.org/10.1016/j.jaip.2021.07.058
Vitale C, Maglio A, Pelaia C, D’Amato M, Ciampo L, Pelaia G, Molino A, Vatrella A. Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting. J Clin Med. 2023 Jan 27;12(3):985. https://doi.org/10.3390/jcm12030985
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):34 3-373. https://doi.org/10.1183/09031936.00202013
Cushen B, Menzies-Gow A. Benralizumab: an updated treatment of eosinophilic asthma. Expert Rev Respir Med. 2020 May;14(5):43 5-444. https://doi.org/10.1080/17476348.2020.1739526

Close metadata